ІСТОРИЧНІ АСПЕКТИ КЛАСИФІКАЦІЇ НЕХОДЖКІНСЬКИХ ЛІМФОМ І СУЧАСНИЙ СТАН ПРОБЛЕМИ ВИЗНАЧЕННЯ ПРОГНОЗУ ПРИ ДИФУЗНИХ В-ВЕЛИКОКЛІТИННИХ ЛІМФОМАХ
Ключові слова:
неходжкінські дифузні В-великоклітинні лімфоми, класифікація, групи ризику, молекулярні підтипи, імуногістохімічні маркери прогнозуАнотація
У статті подано історичний ракурс класифікацій минулих років та особливості останніх класифікацій дифузних В-великоклітинних лімфом.
Детально проілюстровано поділ на прогностичні підгрупи дифузних
В-великоклітинних лімфом, зміни факторів ризику з удосконаленням терапії та недосконалість існуючих прогностичних моделей. Представлено
історію відкриття молекулярних підтипів дифузних В-великоклітинних
лімфом і прогностичне значення основних імуногістохімічних маркерів певного підтипу неходжкінських лімфом.
Посилання
Филоненко КС, Крячок ИА, Алексик ЕМ, Титоренко ИБ и др. Терапия пациентов с ДВККЛ: мировой опыт в украинской медицине. Клин онкол 2011; (4 (4)): 82–7.
Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780–95.
Harris NL, Jaffe ES, Stein H, et al. A revised EuropeanAmerican classification of lymphoid neoplasms: a proposal from
International Lymphoma Study Group. Blood 1997; 84: 924–1361.
Mason DY, Harris NL (eds).Human Lymphoma: clinical implication of REAL classification. London: Springer-Verlag, 1999. 554 p.
Jaffe ES, Harris NL, Stein H, et al. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001. 351 р.
Guttierrez M, Wilson WH, Abraham EJ, Atlegra CJ. NonHodgkin’s lymphoma. In: Bethesda Handbook of Clinical Oncology. Philadelphia: Lippincott Williamsa Wilkins, 2001: 319–32.
Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical Advisory Committee meeting , Airlie House, Virginia, November, 1997. J Clin Oncol 1999; 17: 3835–49.
Rappaport H. Tumors of the hematopoietic system. Atlas of tumor pathology. Washington: US Armed Forces Inst Pathol, 1996. 442 p.
Hu Y, Yang K, Krause JR. Diffuse large B-cell lymphoma, differential diagnosis and molecular stratification. N A J Med Sci 2011; 4 (2): 67–76.
Gatter KC, Warnke RA. Diffuse large B-cell lymphoma. In: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001: 171–4.
Sehn LH. Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. ASH Education Book 2012; 2012 (1): 402–9.
[No authors listed]. A predictive model for aggressive nonHodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–94.
Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109 (5): 1857–61.
Zhou Z, Sehn HL, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014; 123 (6): 837–42.
Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403 (6769): 503–11.
Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene expression profiling and supervised machine learning. Nat Med 2002; 8: 68–74.
Lossos IS. Diffuse large B-cell lymphoma: from gene expression profiling to prediction of outcome. Biol Blood Marrow Transplant 2008; 14 (1): 108–11.
Alizadeh AA, Gentles AJ, Alencar AJ, Liu CL. Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood 2011; 118 (5): 1350–8.
Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103 (1): 275–82.
Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009; 15 (17): 5494–502.
Meyer PN, Fu K, Greiner TC, et al.Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011; 29 (2): 200–7.
Ilić I, Mitrović Z, Aurer I, et al. Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell
lymphoma patient treated with CHOP-like chemotherapy with and without rituximab. Int J Hematol 2009; 90 (1): 74–8.
Costa LJ, Feldman AL, Micallef IN, et al. Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation. Br J Haematol 2008; 142 (3): 404–12.
Lin P, Medeiros LJ. High-grade B-cell lymphoma/leukemia associated with t(14;18) and 8q24/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis. Haematologica 2007; 92 (10): 1297–301.
Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood 2011; 117 (8): 2319–31.
Nyman H, Adde M, Karjalainen-Lindsberg ML, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007; 109 (11): 4930–5.
van Imhoff GW, Boerma EG, van der Holt B, et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 4135–42.
Berglund M, Thunberg U, Amini RM, et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol 2005; 18: 1113–20.
Colomo L, López-Guillermo A, Perales M. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101 (1): 78–84.
Iida S, Rao PH, Butler M, et al. Deregulation of MUM1/ IRF4 by chromosomal translocation in multiple myeloma. Nat Genet 1997; 17: 226–30.
Chang KC, Huang GC, Jones D, et al. Distribution and prognosis of WHO lymphoma subtypes in Taiwan reveals a low incidence of germinal-center derived tumors. Leuk Lymphoma 2004; 45 (7): 1375–84.
Fabiani B, Delmer A, Lepage E. CD10 expression in diffuse large B-cell lymphomas does not influence survival. Virchows Arch 2004; 445 (6): 545–51.
Ohshima K, Kawasaki C, Muta H, et al. CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis. Histopathology 2001; 39 (2): 156–62.
Winter JN, Weller EA, Horning SJ. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP
or R-CHOP: a prospective correlative study. Blood 2006; 107 (11): 4207–13.
Tsujimoto Y, Gorham J, Cossman J, et al.The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 1985; 229: 1390–3.
Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin’s lymphoma. Blood 1997; 90: 244–51.
Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: apharmacodynamic approach with high efficacy. Blood 2002; 99: 2685–93.
Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post germinal center biomarkers. J Clin Oncol 2008; 26: 2717–24.
Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101: 4279–84.
Iqbal J, Meyer PN, Smith L, et al. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma
treated with CHOP-like therapy and rituximab. Clin Cancer Res 2011; 17: 7785–95.
Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression : a report from the International DLBCL RituximabCHOP Consortium Program Study. Blood 2013; 121 (14): 2715–24.
Hinds P, Finlay C, Levine AJ. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol 1989; 63 (2): 739–46.
Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358 (6381): 15–6.
Hermeking H, Lengauer C, Polyak K, et al. 14–3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997; 1 (1): 3–11.
Kerbauy FR, Colleoni GW, Saad ST, et al. Detection and possible prognostic relevance of p53 gene mutations in diffuse large B-cell lymphoma. An analysis of 51 cases and review of the literature. Leuk Lymphoma 2004; 45 (10): 2071–8.
Leroy K, Haioun C, Lepage E, et al. p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Ann Oncol 2002; 13 (7): 1108–15.
Young KH, Leroy K, Møller MB, et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 2008; 112 (8): 3088–98.
Zainuddin N, Berglund M, Wanders A, et al. TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype. Leuk Res 2009; 33 (1): 60–6.
Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99 (4): 1136–43.
Xie Y, Bulbul MA, Ji L, et al. p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study. Am J Clin Pathol 2014; 141 (4): 593–604.
